Research Topics
Species | S SienaSummaryAffiliation: Niguarda Hospital Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumabAndrea Sartore-Bianchi
Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
J Clin Oncol 25:3238-45. 2007..The present study was aimed at assessing the predictive role of EGFR GCN, in terms of clinical outcome, in patients treated with panitumumab...
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu
Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
Lancet Oncol 9:39-44. 2008..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapySalvatore Siena
Dipartimento di Oncologia ad Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
Crit Rev Oncol Hematol 48:S39-47. 2003..These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives...
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumabS Siena
Ospedale Niguarda Ca Granda, Milan, Italy
Br J Cancer 97:1469-74. 2007..Overall survival favoured no PD patients vs PD patients alive at week 8. Lack of disease progression was associated with better symptom control, HRQoL, and OS...
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancerSalvatore Siena
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
J Natl Cancer Inst 101:1308-24. 2009..The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward individualized treatment for patients with metastatic colorectal cancer...
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyS Siena
Divisione Oncologia Falck, Ospedale Niguarda Ca Granda, Milan
Ann Oncol 21:655-61. 2010..This phase II study evaluated the efficacy of single-agent therapy with alternating weekly, dose-dense temozolomide in pretreated patients with brain metastases prospectively stratified by primary tumor type...
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedicationSalvatore Siena
Division of Medical Oncology Falck, Niguarda Ca Granda Hospital, Milan, Italy
Cancer 116:1827-37. 2010....
High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancerP Pedrazzoli
SC Oncologia Medica Falck, Dipartimento Oncologico, Ospedale Niguarda Ca Granda, 1 20162 Milano, Italy
J Chemother 16:108-11. 2004..They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies...
Cetuximab for treatment of metastatic colorectal cancerG Cerea
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
Ann Oncol 17:vii66-7. 2006....
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adultsP Pedrazzoli
Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milano, Italy
Ann Oncol 17:1479-88. 2006..In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas...
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignanciesPaolo Pedrazzoli
Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
Cancer 94:2409-15. 2002..The objectives of the current study were to evaluate the feasibility of this approach in terms of toxicity and engraftment and to document evidence of GVT effects...
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAndrea Sartore-Bianchi
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
PLoS ONE 4:e7287. 2009....
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort studyMauro Moroni
The Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy
Lancet Oncol 6:279-86. 2005..INTERPRETATION: We propose that the response to antiEGFR treatment has a genetic basis and suggest that patients might be selected for treatment on the basis of EGFR copy number...
Rationale and clinical results of multi-target treatments in oncologyA Sartore-Bianchi
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
Int J Biol Markers 22:S77-87. 2007..This review will deal with the rationale underlying the multi-targeted approach and with the available clinical experience with multi-targeted agents, especially focusing on molecules with anti- EGFR mechanisms of action...
Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumorsM Moroni
The Falck Division of Medical Oncology, Department of Oncology and Hematology, Ospedale Niguarda Ca Granda, I 20162 Milan, Italy
Clin Cancer Res 7:2770-5. 2001....
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapyS Siena
Falck Division of Medical Oncology, Department of Hematology and Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
J Clin Oncol 18:1360-77. 2000..To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation...
GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasiaI Turin
Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, Milan, Italy
Cytotherapy 9:499-507. 2007..We have now investigated the possibility of producing large amounts of autologous anti-tumor CTL, in compliance with good manufacturing practices, for in vivo use...
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low fR Mortarini
Division of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Cancer Res 57:5534-41. 1997..These results suggest that CD34+- and monocyte-derived DCs are not functionally equivalent APCs for the activation of low-frequency peptide-specific CTLps...
Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factorsS Siena
Cristina Gandini Unit, Istituto Nazionale Tumori, Milan, Italy
Exp Hematol 21:1583-90. 1993....
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancerA Sartore-Bianchi
The Falck Division of Medical Oncology, Department of Oncology, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, Milan, Italy
Cancer Treat Rev 36:S1-5. 2010..This review will focus on current knowledge regarding the molecular landscape of mCRC including and beyond KRAS, and will summarize novel rationally-developed combinatorial regimens that are being evaluated in early clinical trials...
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999P Pedrazzoli
S C Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
Bone Marrow Transplant 32:489-94. 2003..Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome...
Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II studyM Moroni
Divisione Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milano, Italy
J Chemother 15:394-9. 2003..BMV, administered second-line in an outpatient setting, has activity similar to that of the taxanes, but with a more acceptable toxicity profile including an absence of alopecia...
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodiesAndrea Sartore-Bianchi
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
Cancer Res 69:1851-7. 2009..When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified...
Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemiaIlaria Schiavetto
Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
Chemotherapy 54:417-20. 2008..In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue...
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow TransplantationSimona Secondino
Divisione Oncologica Falck, Ospedale Niguarda Ca Granda, Milan, Italy
Haematologica 92:418-20. 2007..Our study may suggest that an immune-mediated effect cannot be excluded in some STS...
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancerAndrea Sartore-Bianchi
The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
Target Oncol 5:19-28. 2010..We suggest that in the near future comprehensive molecular analysis of the entire oncogenic pathway triggered by the EGFR should be performed, thus enhancing the prediction ability of individual markers...
Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusionRoberta Schiavo
Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
Anticancer Res 27:3273-8. 2007..In the present study, we report the establishment and characterization of a primary Ewing's sarcoma cell line (LDS-Falck 01)...
Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapySimona Secondino
Oncologia Medica Falck, Ospedale Niguarda Ca Granda, 20162 Milano, Italy
Anticancer Res 28:3991-2. 2008....
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemiaPaolo Pedrazzoli
The Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, Milan, Italy
Cancer 115:1169-73. 2009..In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue...
EGFR FISH in colorectal cancer: what is the current reality?Mauro Moroni
Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, 20162 Milan, Italy
Lancet Oncol 9:402-3. 2008
Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropeniaRiccardo Ricotta
Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
Future Oncol 2:667-76. 2006..Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells...
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alphaPaolo Pedrazzoli
Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
J Clin Oncol 26:1619-25. 2008..We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin...
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancerSalvatore Siena
Divisione Oncologia Medica Falck, Dipartimento di Oncologia ed Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
Oncol Rep 10:715-24. 2003..Pegfilgrastim may offer patients more effective protection against neutropenic complications of chemotherapy with fewer injections and less disruption to their lives...
Treatment of metastatic neuroendocrine carcinomas based on WHO classificationSalvatore Artale
Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milan, Italy
Anticancer Res 25:4463-9. 2005..Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs...
Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphomaPier Adelchi Ruffini
Divisione Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
Curr Gene Ther 5:511-21. 2005....
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical resultsS Secondino
Falck Medical Oncology, Niguarda Ca Granda Hospital, Milano, Italy
Ann Oncol 23:435-41. 2012..With the aim of favoring in vivo T-cell expansion, we optimized our cell therapy approach by administering higher doses of EBV-specific CTLs, following lymphodepleting chemotherapy...
The effect of anticonvulsant drugs on blood levels of methotrexateM Riva
Department of Neurology, Niguarda Ca Granda Hospital, Milan, Italy
J Neurooncol 48:249-50. 2000..We report how even the results of high dose sequential chemotherapy can be influenced by antiepileptic drugs...
Survival of adults treated for medulloblastoma using paediatric protocolsFilippo Spreafico
Paediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Eur J Cancer 41:1304-10. 2005....
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemiaS Siena
Divisione Oncologia Medica Falck, Piazza Ospedale Maggiore 3, 20162 Milan, Italy
Haematologica 84:369-72. 1999..Molecular analysis of the t(5;10)(q33;q22) translocation breakpoint is currently underway in order to identify genes located in this region which might provide insights into the pathogenesis of atypical myeloproliferative disorders...
Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumorsM Renga
Divisione Oncologia Medica Falck, Dipartimento di Oncologia ed Ematologia, Ospedale Niguarda Ca Granda, Milan, Italy
Ann Oncol 14:1177-84. 2003..In the present article we review the biological basis, development and early clinical results of this novel immunotherapeutic approach for solid tumors...
Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodiesSalvatore Siena
Falck Division of Medical Oncology, Department of Oncology and Hematology, Niguarda Ca' Granda Hospital, Milan, Italy
Suppl Tumori 1:S46-8. 2002
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancerSalvatore Artale
J Clin Oncol 26:4217-9. 2008
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapyJohan Vansteenkiste
Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
J Natl Cancer Inst 94:1211-20. 2002..This phase III study compared the safety and efficacy of darbepoetin alfa with placebo in patients with lung cancer receiving chemotherapy...
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerEric Van Cutsem
Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
J Clin Oncol 25:1658-64. 2007..We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy...
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trialLuigi Dogliotti
Unit of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano Torino, Italy
Eur Urol 52:134-41. 2007....
Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology unitsLara Maria Pasetto
Oncologia Medical 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy
Anticancer Res 28:1813-20. 2008..In this paper, we highlight the pattern of palliative treatment and possible effects on survival among elderly patients...
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapiesSilvia Benvenuti
Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy
Cancer Res 67:2643-8. 2007..They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/RAF/MAPK signaling pathways in CRC patients...
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerDavid Cunningham
Royal Marsden Hospital, London, United Kingdom
N Engl J Med 351:337-45. 2004..We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan...
HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forumRoman Perez-Soler
Department of Oncology, Hofheimer 100, Montefiore Medical Center Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA
Oncologist 10:345-56. 2005..The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies...
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerRafael G Amado
Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
J Clin Oncol 26:1626-34. 2008..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
Iron supplement in cancer patients receiving erythropoietinPaolo Pedrazzoli
J Clin Oncol 22:4428; author reply 4428-9. 2004
Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical siblingDaniela Montagna
Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi, 27100 Pavia, Italy
Int J Cancer 110:76-86. 2004..Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy...
Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in ItalyLara Maria Pasetto
Istituto Oncologico Veneto, IRCCS, Oncologia Medica 2, Padova, Italy
Anticancer Res 27:3601, 3603-8. 2007..The aim of this retrospective analysis was to evaluate the differences of 1-year treatment and chemotherapy related-toxicity in elderly colorectal cancer (CRC) patients in different Italian medical oncology units...
[4th National Conference of Medical Oncology. Evolution of the technology and clinical objectives of antitumor therapy]Salvatore Siena
SC Divisione Oncologia Medica Falck, , Milano
Tumori 88:A1-4. 2002
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytesPatrizia Comoli
Laboratorio di Ricerca Area Trapianti e Oncoematologia Pediatrica, IRCCS Policlinico S Matteo, V le Golgi 19, 27100 Pavia, Italy
J Clin Oncol 23:8942-9. 2005..We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments...
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantationJacopo Peccatori
Hematology-Bone Marrow Transplant Unit, Istituto Scientifico H. San Raffaele, Milano, Italy
Cancer 104:2099-103. 2005....
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosisVittorio Perfetti
Amyloid Center, IRCCS Policlinico S. Matteo P. le Golgi 2, 27100 Pavia, Italy
Haematologica 91:1635-43. 2006..Additional therapy should be considered if no hematologic response is observed at +3 months after ASCT...
Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancerMauro Moroni
Cancer 97:2926-7; author reply 2927-8. 2003
